Short answer
Aura Biosciences, Inc. (AURA) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$26M
- −24.2% YoY · +3.3% QoQ
- EPS (diluted)
- −$0.38
- +9.5% YoY · +17.4% QoQ
Source: XBRL data from the Aura Biosciences, Inc. (AURA) Q3 2025 10-Q on SEC EDGAR. USD.
Aura Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Net loss $80.6 million for nine months ended September 30, 2025, versus $61.1 million in 2024
- Cash and securities expected to fund operations into first half of 2027, but insufficient through bel-sar regulatory approval
- Bel-sar development faces heightened regulatory complexity because ocular delivery requires a device and laser activation
- Bel-sar remains the sole product candidate, making business performance dependent on one program
- Additional financing may dilute shareholders, including through May 2025 warrant exercises
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aura Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.